Business, energy, technology, markets and global industry news from Business News Today

Summit Therapeutics

Pharma & Biotech

Ivonescimab delayed lung cancer progression. Why did the FDA still reject Summit’s application?

FDA rejects Summit's ivonescimab application over survival evidence. Discover what the decision means for HARMONi, investors and future trials.

Read More
Pharma & Biotech

Ivonescimab clears half of lung tumours before surgery, but can Akeso prove lasting benefit?

Akeso's ivonescimab delivered 70.1% major pathological response in resectable lung cancer. The Phase 2 trial reveals promise and limitations.

Read More
Pharma & Biotech

Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab

Summit Therapeutics and Lunit will study AI-derived tumor biomarkers for ivonescimab, while clinical validation and patient-selection benefits remain unproven.

Read More
Pharma & Biotech

Why the PD-L1-high subgroup could be crucial for Summit Therapeutics’ global strategy

Summit shares rise after ivonescimab delivers 30.8-month survival versus 22.6 months for pembrolizumab in China’s HARMONi-2 trial.

Read More
Pharma & Biotech

Lancet Oncology publishes Summit’s global ivonescimab Phase 3 with PFS at 6.8 months versus 4.4

Global HARMONi data show ivonescimab plus chemotherapy reduced progression or death risk by 48% after third-generation EGFR-TKI failure, while overall survival had not reached statistical significance at the primary analysis.

Read More
Pharma & Biotech

What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC

Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.

Read More
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More
Pharma & Biotech

Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?

Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.

Read More